Literature DB >> 16193889

Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.

R H C Lazeron1, J B Boringa, M Schouten, B M J Uitdehaag, E Bergers, J Lindeboom, M I Eikelenboom, P H Scheltens, F Barkhof, C H Polman.   

Abstract

Multiple sclerosis (MS) is a multifocal demyelinating disease of the central nervous system, with lesions widespread through the brain and spinal cord. An important manifestation is cognitive impairment, which, though difficult to measure, may have a major social impact. To better understand the relationship between structural tissue damage and cognitive impairment, we examined the extent and spatial distribution of brain lesions, as measured by magnetic resonance imaging (MRI), in relation to abnormal cognitive performance as measured by the Brief Repeatable Battery (BRB) in 82 MS patients. Possible confounders, like fatigue, pain and depression were also assessed. Brain MR image analysis included hyperintense T2 and hypointense T1 lesion load in the whole brain and the four lobes separately, as well as whole brain volume measurements. Cognitive impairment (defined as more than two abnormal tests) was found in 67% of the patients. Moderately strong correlations were found between the subtests of the BRB and the lesion loads in the brain regions hypothesized to be associated with that cognitive test, although these correlations were in general not much stronger than those between the subtests and the overall lesion load (due to strong interrelationships). The Spatial Recall Test correlated best with parietal lesion load; the Symbol Digit Modalities Test, the Paced Auditory Serial Addition Task (PASAT) and the Word List Generation best with frontal, parietal and temporal lesion load; while the Verbal List Generation Test Index correlated only with atrophy. Atrophy and lesion load were the main factors determining the test scores, explaining 10-25% of the variance in the test results, and were more important than fatigue, pain and depression; only depression had a minor, but significant, additional effect on the PASAT. In conclusion, cognitive impairment in MS is moderately dependent on amount (and distribution) of structural brain damage, especially in the more physically impaired patients group.

Entities:  

Mesh:

Year:  2005        PMID: 16193889     DOI: 10.1191/1352458505ms1201oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  36 in total

1.  Validity of a computerized version of the symbol digit modalities test in multiple sclerosis.

Authors:  Nadine Akbar; Kimia Honarmand; Nancy Kou; Anthony Feinstein
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

2.  Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis.

Authors:  P G Sämann; M Knop; E Golgor; S Messler; M Czisch; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

3.  Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study.

Authors:  Alvino Bisecco; Maria A Rocca; Elisabetta Pagani; Laura Mancini; Christian Enzinger; Antonio Gallo; Hugo Vrenken; Maria Laura Stromillo; Massimiliano Copetti; David L Thomas; Franz Fazekas; Gioacchino Tedeschi; Frederik Barkhof; Nicola De Stefano; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2015-04-14       Impact factor: 5.038

4.  Compensatory activations in patients with multiple sclerosis during preserved performance on the auditory N-back task.

Authors:  Cristina Forn; Alfonso Barros-Loscertales; Joaquín Escudero; Vicente Benlloch; Salvador Campos; Maria Antònia Parcet; César Avila
Journal:  Hum Brain Mapp       Date:  2007-05       Impact factor: 5.038

5.  How Do Pain, Fatigue, Depressive, and Cognitive Symptoms Relate to Well-Being and Social and Physical Functioning in the Daily Lives of Individuals With Multiple Sclerosis?

Authors:  Anna L Kratz; Tiffany J Braley; Emily Foxen-Craft; Eric Scott; John F Murphy; Susan L Murphy
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

6.  Pain, Fatigue, and Cognitive Symptoms Are Temporally Associated Within but Not Across Days in Multiple Sclerosis.

Authors:  Anna L Kratz; Susan L Murphy; Tiffany J Braley
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

Review 7.  Causes, effects and connectivity changes in MS-related cognitive decline.

Authors:  Carolina de Medeiros Rimkus; Martijn D Steenwijk; Frederik Barkhof
Journal:  Dement Neuropsychol       Date:  2016 Jan-Mar

8.  Ecological Momentary Assessment of Pain, Fatigue, Depressive, and Cognitive Symptoms Reveals Significant Daily Variability in Multiple Sclerosis.

Authors:  Anna L Kratz; Susan L Murphy; Tiffany J Braley
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.